Counseling on Dose Delays and Reductions and Extending the Dosing Interval

One panelist reassures a responding patient whose dose is held that benefit does not depend on every-3-week dosing and that the eye has the ability to heal on its own, noting that patients at longer intervals in the study maintained benefit, some doing better by staying on treatment longer. The panel recommends reassessing at the start of the next cycle rather than scheduling frequent eye visits. The panelist also adds that once the dose is lowered for ocular toxicity it should not be raised again. The moderator then asks how to counsel a patient in a very good partial response who is anxious about not reaching a complete response, and the panel then delve into how they would counsel that patient.